Vol. 9, Special Issue 6, Part G (2025)

Danofloxacin is a fluoroquinolone antimicrobial agent used exclusively in veterinary medicine. It exhibits broad-spectrum activity against several Gram-negative bacterial pathogens such as Escherichia coli, Klebsiella, Salmonella, and some Gram-positive organisms like Staphylococcus species, and thus has potential therapeutic applications for treating bacterial infections in poultry. Plasma protein binding significantly influences the pharmacokinetics and pharmacodynamics of antimicrobial drugs. Despite its clinical relevance, data on the plasma protein binding of danofloxacin in broiler chickens remain scarce. This study aimed to determine the extent of danofloxacin binding to plasma proteins in healthy broilers using in vitro equilibrium dialysis, with subsequent quantification by Ultra High-Performance Liquid Chromatography. Results showed that danofloxacin’s plasma protein binding ranged from 24.99 ± 3.38% to 33.81 ± 4.68% across different concentrations, with an average binding of 28.84 ± 1.27%. These findings suggest that danofloxacin exhibits low to moderate plasma protein binding in broiler chickens and offer important baseline data to better understand the drug's kinetic behaviour in this species.